Mercaptopurine

What is Mercaptopurine?

Mercaptopurine is an antimetabolite chemotherapy medication that belongs to a class of drugs called purine analogs. It is primarily used to treat certain types of blood cancers, particularly acute lymphoblastic leukemia (ALL), and is also prescribed for inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. This medication works by interfering with DNA and RNA synthesis in rapidly dividing cells.

Uses

Mercaptopurine has several established medical uses:

• Acute lymphoblastic leukemia (ALL): Used as part of combination chemotherapy regimens for both initial treatment and maintenance therapy in children and adults
• Acute myeloid leukemia: Sometimes included in treatment protocols, particularly for maintenance therapy
• Crohn’s disease: Prescribed as an immunosuppressive agent to reduce inflammation and maintain remission in patients with moderate to severe disease
• Ulcerative colitis: Used to help control inflammation in the colon and maintain long-term remission
• Non-Hodgkin lymphoma: Occasionally used in specific treatment combinations for certain subtypes of lymphoma

How it works

Mercaptopurine mimics naturally occurring purines, which are essential building blocks for DNA and RNA synthesis. Once inside cells, it gets converted into active metabolites that interfere with the production of genetic material, preventing rapidly dividing cells from reproducing effectively. This mechanism makes it particularly effective against cancer cells and overactive immune cells that contribute to inflammatory conditions.

Side effects

Common side effects:

Submit Your Paper

• Nausea and vomiting
• Loss of appetite
• Fatigue and weakness
• Mouth sores or ulcers
• Diarrhea
• Hair loss (alopecia)
• Skin rash
• Increased susceptibility to infections

Serious side effects requiring immediate medical attention:

• Severe bone marrow suppression leading to dangerous drops in blood cell counts
• Liver toxicity, including hepatitis and liver failure
• Severe infections due to immunosuppression
• Pancreatitis (inflammation of the pancreas)
• Secondary cancers, particularly skin cancers

Warnings and precautions

• Pregnancy: Mercaptopurine can cause birth defects and should not be used during pregnancy unless the potential benefits outweigh the risks. Women of childbearing age should use effective contraception during treatment.
• Genetic testing: Patients with certain genetic variations in the TPMT or NUDT15 enzymes may require dose adjustments or alternative treatments due to increased risk of severe toxicity.
• Liver function monitoring: Regular liver function tests are essential as the drug can cause serious liver damage, particularly in patients with pre-existing liver conditions.
• Blood count monitoring: Frequent blood tests are required to monitor for bone marrow suppression and potentially dangerous drops in white blood cells, red blood cells, and platelets.
• Immunosuppression: Patients should avoid live vaccines and take precautions to prevent infections, as the medication significantly weakens the immune system.

Interactions

• Allopurinol: Significantly increases mercaptopurine levels and toxicity; dose reduction of mercaptopurine is required if used together
• Warfarin and other anticoagulants: May enhance or reduce anticoagulant effects, requiring careful monitoring of blood clotting parameters
• ACE inhibitors: May increase the risk of severe blood disorders when combined with mercaptopurine
• Live vaccines: Should be avoided due to increased risk of infection from the vaccine
• Trimethoprim-sulfamethoxazole: May increase bone marrow suppression when used concurrently
• Aminosalicylates (mesalamine, sulfasalazine): May interfere with mercaptopurine metabolism, potentially increasing toxicity
• Methotrexate: Combined use may increase liver toxicity and require dose adjustments
• Febuxostat: Similar to allopurinol, may increase mercaptopurine toxicity and require dose modifications

Check interactions with the GMJ Interaction Checker

Dosage

Adult dosages vary significantly depending on the condition being treated and individual patient factors. For acute leukemia, typical starting doses range from 1.5 to 2.5 mg per kilogram of body weight daily, often given as part of complex multi-drug protocols. For inflammatory bowel diseases, initial doses typically range from 50 to 100 mg daily, with maintenance doses adjusted based on patient response and tolerance. Dosing may need to be reduced in patients with certain genetic variations or those taking interacting medications. All dosing decisions should be made by a qualified healthcare provider based on individual patient needs, regular monitoring results, and treatment response.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).